| Issue Date | Title | Author(s) |
| 2017 | Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China | Shi, Yuankai; Jia, Bo; Xu, Wei; Li, Wenyu; Liu, Ting; Liu, Peng; Zhao, Weili; Zhang, Huilai; Sun, Xiuhua; Yang, Haiyan; Zhang, Xi; Jin, Jie; Jin, Zhengming; Li, Zhiming; Qiu, Lugui; Dong, Mei; Huang, Xiaobing; Luo, Yi; Wang, Xiaodong; Wang, Xin; Wu, Jianqiu; Xu, Jingyan; Yi, Pingyong; Zhou, Jianfeng; He, Hongming; Liu, Lin; Shen, Jianzhen; Tang, Xiaoqiong; Wang, Jinghua; Yang, Jianmin; Zeng, Qingshu; Zhang, Zhihui; Cai, Zhen; Chen, Xiequn; Ding, Kaiyang; Hou, Ming; Huang, Huiqiang; Li, Xiaoling; Liang, Rong; Liu, Qifa; Song, Yuqin; Su, Hang; Gao, Y |
| Aug-2020 | The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): A multicenter, open-label, single-arm, phase 2 trial | Shi, Yuankai; Wu, Jianqiu; Wang, Zhen; Zhang, Liling; Wang, Zhao; Zhang, Mingzhi; Cen, Hong; Peng, Zhigang; Li, Yufu; Fan, Lei; Guo, Ye; Ma, Liping; Cui, Jie; Gao, Yuhuan; Yang, Haiyan; Zhang, Hongyu; Wang, Lin; Zhang, Weihua; Zhang, Huilai; Xie, Liping; Jiang, Ming; Zhou, Hui; Shuang, Yuerong; Su, Hang; Ke, Xiaoyan; Jin, Chuan; Du, Xin; Du, Xin; Liu, Li; Xi, Yaming; Ge, Zheng; Feng, Ru; Zhang, Yang; Zhou, Shengyu; Xie, Fan; Gao, Chao |
| 15-Nov-2022 | Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China | Song, Yuqin; Ying, Zhitao; Yang, Haiyan; Guo, Ye; Li, Wenyu; Zou, Dehui; Wu, Jianqiu; Tian, Alex; Huang, Tony; Zhou, Zisong; Ma, Meilin; Yang, Su; Qin, Yun; Zhu, Jun |
| 2-Nov-2023 | First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B- Cell Non-Hodgkin Lymphoma (B-NHL) | Song, Yuqin; Zhou, Keshu; Jing, Hongmei; Wu, Jianqiu; Yang, Haiyan; Bai, Yu; Fang, Ke; Liu, Ziyi; Zhu, Jun; Cheah, Chan Y. |
| 2-Nov-2023 | Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8) | Song, Yuqin; Malpica, Luis; Cai, Qingqing; Zhao, Weili; Zhou, Keshu; Wu, Jianqiu; Zhang, Huilai; Ding, Kaiyang; Liu, Yao; Li, Zengjun; Mehta-Shah, Neha; Zhang, Liling; Zheng, Meifang; Jin, Jie; Yang, Haiyan; Shuang, Yuerong; Yoon, Dok Hyun; Gao, Sujun; Li, Wenyu; Zhai, Zhimin; Zou, Liqun; Xi, Yaming; Koh, Youngil; Li, Fei; Prince, Miles; Zhou, Hui; Lin, Lie; Liu, Hui; Yang, Zhenfan; Kim, Won Seog; Zhu, Jun |
| 15-Nov-2022 | XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma:Updates of the Phase Ib Touch Study | Huang, Huiqiang; Gao, Yan; Zhang, Huilai; Zhou, Keshu; Wu, Jianqiu; Cai, Zhen; Jing, Hongmei; Fan, Lei; Lou, Sai; Fei, Yizhou; Wang, Aihua; Lynch, Kevin |
